

# XLIFE SCIENCES AG

ISIN: CH0461929603 WKN: 46192960 Asset Class: Stock

## Company

2024/07/17 17:30:08



Price

29.00 CHF

Difference ▲ 1.40% (0.40)



## Contact Details

XLIFE SCIENCES AG Tel: +41-44-385-84-60  
 -- Fax: +  
 Talacker 35 Web: <http://www.xlifesciences.ch>  
 8001 Zürich E-mail: [info@xlifesciences.ch](mailto:info@xlifesciences.ch)

## Company Profile

Xlife Sciences AG focuses on the value development of performance promising technologies in life sciences. The company was founded in 2019 and is headquartered in Zurich, Switzerland.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	18,118,000		1,245,000		2,472,000	
<b>Common stock capital</b>		5,592,000		5,283,000		5,059,000
<b>Fixed assets</b>	493,875,000		488,984,000		477,592,000	
<b>Equity capital of a company</b>		365,036,000		337,703,000		319,219,000
<b>Cash and cash equivalents</b>	218,000		221,000		1,956,000	
<b>Accrued liabilities</b>		67,000		29,000		105,000
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		5,831,000		1,929,000		2,329,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		141,125,000		150,596,000		158,515,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		0		0		0
<b>Total assets</b>	511,993,000	511,993,000	490,230,000	490,230,000	480,064,000	480,064,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	IFRS	IFRS	IFRS
<b>Employees</b>	-	-	-
<b>Equity ratio</b>	90.22%	89.79%	88.99%
<b>Debt-equity ratio</b>	10.84%	11.37%	12.37%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	-38.41%	-36.29%	-0.15%

# XLIFE SCIENCES AG

ISIN: CH0461929603 WKN: 46192960 Asset Class: Stock

## Income statement

	2023	2022	2021
Turnover	988,000	1,027,000	806,000
Net income	14,879,000	14,312,000	53,418,000
EBIT	13,003,050	13,868,107	55,880,253
Operating income before taxes	12,338,000	13,061,000	54,166,000
Cash Flow	171,000	-4,607,000	-4,324,000
Net interest income	-357,000	-479,000	-393,000
Research and development expenses	250,000	144,000	166,000
Income taxes	-4,739,000	-4,739,000	-80,000
Result from investments in subsidiaries, associates and other	-7,804,000	-9,022,000	-971,000
Revenues per employee	-	-	-

## Board of Directors

Norbert Windhab	Member of the administrative board
Désirée Dosch	Member of the administrative board
Mark Müller	Member of the administrative board
David Deck	Chairman of the administrative board

## Members of Management Board

Oliver R. Baumann	Chairman of Managing Board
Frank Plöger	Member of Executive Committee
Carl von Halem	Member of Executive Committee